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To determine whether [
18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) could predict the pathological response
in oesophageal cancer after only the first week of neoadjuvant chemoradiation. Thirty-two patients with localised oesophageal cancer
had a pretreatment PET scan and a repeat after the first week of chemoradiation. The change in mean maximum standardised uptake
value (SUV) and volume of metabolically active tissue (MTV) was compared with the tumour regression grade (TRG) in the final
histology. Those who achieved a TRG of 1 and 2 were deemed responders and 3–5 nonresponders. In the responders (28%), the
SUV fell from 12.6 (76.3) to 8.1 (72.9) after 1 week of chemoradiation (P¼0.070). In nonresponders (72%), the results were 9.7
(75.4) and 7.1 (73.8), respectively (P¼0.003). The MTV in responders fell from 36.6 (722.7) to 22.3 (710.4) cm
3 (P¼0.180),
while in nonresponders, this fell from 35.9 (736.7) to 31.9 (752.7)cm
3 (P¼0.405). There were no significant differences between
responders and nonresponders. The hypothesis that early repeat FDG-PET scanning may predict histomorphologic response was not
proven. This may reflect an inflammatory effect of radiation that obscures tumour-specific metabolic changes at this time. This
assessment may have limited application in predicting response to multimodal regimens for oesophageal cancer.
British Journal of Cancer (2006) 95, 1174–1179. doi:10.1038/sj.bjc.6603412 www.bjcancer.com
Published online 3 October 2006
& 2006 Cancer Research UK
Keywords: oesophageal cancer; positron emission tomography; neoadjuvant chemoradiation; response
                                                   
The standard therapy for localised oesophageal carcinoma is
surgical resection (Enzinger and Mayer, 2003). However, local
control and overall survival remain poor, and even after radical
resection and lymphadenectomy, the 5-year survival is at best
approximately 40% (Lerut et al, 1999; Altorki et al,2 0 0 2 ) .I na n
effort to improve outcomes, neoadjuvant approaches, either
chemotherapy alone or combined with radiation therapy, have
been evaluated in randomised clinical trials (Nygaard et al,1 9 9 2 ;L e
Prise et al, 1994; Walsh et al, 1996; Bosset et al, 1997; Kelsen et al,
1998; Urba et al, 2001; Medical Research Council Oesophageal
Cancer Working Group, 2002; Burmeister et al, 2005). The sole
prospective randomised trial to report survival benefit for
neoadjuvant combination chemotherapy and radiation therapy
compared with surgery alone was undertaken at this centre between
1990 and 1995 (Walsh et al, 1996). Although controversial, the use of
this multimodality approach has increased outside of clinical trials,
and the patterns of care studies in the US showed that preoperative
chemoradiation therapy increased from 10.4% during 1992–1994 to
26.6% in 1996–1999 (Suntharalingam et al,1 9 9 9 ) .
The patients who receive maximum benefit from neoadjuvant
combination chemotherapy and radiation therapy (CRT) are those
who achieve a complete pathological response (pCR), with no
residual cancer cells in the primary tumour or lymph nodes. A
pCR occurs in approximately 15–30% of cases, and 3-year survival
rates of approximately 60% irrespective of the applied protocol,
type of histology and tumour stage are achieved (Geh et al, 2001).
A further subdivision of pathological response to neoadjuvant
regimens, the tumour regression grade (TRG) (Mandard et al,
1994), may also identify patterns of incomplete response that may
impact on treatment outcome, and the addition of the pathologic
response to pTNM staging has been recently advocated (Swisher
et al, 2005). Where a cohort of patients may benefit from
neoadjuvant CRT, with pCR and TRG the surrogate markers,
many patients will not be helped, and their prognosis may be
worsened by delay in surgery and by the added risks of surgery in
patients on multimodal protocols (Ancona et al, 2001; Fiorica et al,
2004). A predictor of response or resistance would have potentially
enormous application in optimising outcomes. Moreover, new
markers that function as surrogate or proxy indicators of
histomorphological response may be of great value in the design
of Phase II studies using new treatment regimens including
molecular therapies. At this time, pretreatment demographics,
cross-sectional imaging, histopathologic, molecular or genetic
information have not been of clinical value as early response
predictors.
An alternative approach would be identification of a metabolic
pattern that may emerge early after the induction of treatment,
which might then guide management. [
18F]-fluorodeoxyglucose-
positron emission tomography (FDG PET) scanning may be such a
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spredictive tool. It is already established in the staging of
oesophageal cancer (Kneist et al, 2003), and recent evidence
suggests early response patterns to neoadjuvant chemotherapy that
determine outcome (Downey et al, 2003; Wieder et al, 2004). The
earliest time point identifying response or resistance will have the
greatest potential application, and in this study we tested this
hypothesis after a minimum of 7 days of combination chemo-
radiation. We report herein FDG uptake, using both standardised
uptake value (SUV) and assessment of metabolically active tumour
volume (MTV), that early patterns were not evident that predicted
histomorphologic response.
PATIENTS AND METHODS
Between January 2003 and October 2005, 32 consecutive patients
with histologically confirmed oesophageal carcinoma scheduled to
undergo multimodal therapy underwent an FDG-PET scan at
diagnosis and following the first week of CRT. Each patient gave
informed consent. Pretreatment investigations also included
computerised tomography of the neck, thorax and abdomen, and
oesophagogastroscopy. The criteria for inclusion in the multi-
modal protocol was as follows: age o77; satisfactory performance
status and medical fitness for surgery; a biopsy-proven tumour of
the oesophagus or oesophagogastric junction; and a staged tumour
deemed resectable by the primary surgeon. All patients had, in
addition, a leucocyte count greater than 3500cm
3, a platelet count
above 100000cm
3, serum creatinine less than 1.4mgdl
 1
(124mmoll
 1), no previous chemotherapy or radiation therapy
and no previous cancer other than that of the skin.
The treatment protocol was as described previously (Walsh et al,
1996), with 3–4 weeks of radiation therapy, the first combined
with chemotherapy, further chemotherapy alone in week 5 and
surgery approximately 1 month later. For radiotherapy, the
planning target volume incorporated the gross tumour volume
plus a 4–5cm margin superiorly and inferiorly with 2cm
circumferentially. This was identified using the information gained
from the endoscopy and diagnostic CT scans, as well as by the use
of a barium swallow during simulation. The dose of radiotherapy
was either 40.05Gy in 15 daily fractions over 3 weeks or 44Gy in 22
daily fractions over four and a half weeks. Each dose was
prescribed to the mid-plane using 10–15MV photons. 5-Fluoro-
uracil at 15mgkg
 1 was delivered on days 1–5 and cisplatin at
75mgm
 2 on day 6. Surgery involved transthoracic oesophagec-
tomy including en bloc lymphadenectomy of the abdominal and
mediastinal nodes, and it was not undertaken until the neutrophil
count was consistently above 2000ml
 1 on three successive
occasions in a 2-week period.
FDG-PET imaging
[
18F]-fluorodeoxyglucose-positron emission tomography scans
were performed on all patients as part of their staging and in the
week following completion of the induction combination chemo-
therapy and radiation therapy. The PET images were acquired
on a high-resolution dedicated PET scanner 47–78min after
intravenous injection of 340–450MBq of fluorine-18-flurode-
oxyglucose (
18F-FDG). In so far as was possible, the scanning
conditions were kept constant facilitating comparison of the
pretreatment and intratreatment scans, that is, same acquisition
protocol, reconstruction algorithm and uptake time (mean
Dt¼3.9min). Patients fasted for 6h before imaging to ensure
that serum glucose and endogenous serum insulin levels were low
at the time of FDG administration. Blood glucose levels were
measured before each FDG-PET scan. Whole-body scans extending
from base of skull to mid-thigh were obtained in 2-D mode on
either the GE-supplied PET Advance scanner or Discovery-ST PET/
CT scanner. The early repeat image was always performed on the
same scanner as the initial. The images were reconstructed using
ordered subsets expectation maximum iterative reconstruction.
Semiquantitative measurements of metabolic uptake in FDG-
avid tumours following pretreatment and intratreatment scans
were compared and evaluated for their potential to predict
histopathological response to CRT. The tumour FDG uptake was
measured using a region of interest (ROI) method (Stahl et al,
2004). Briefly, a cylindrical ROI with a diameter of 1.5cm was
manually placed over the tumour site on the hottest trans-axial
slice, avoiding the edges of the tumour. The mean activity
concentration within the ROI was determined and expressed as
the SUV, where SUV is the ratio of the activity in the tissue to the
decay-corrected activity injected into the patient. This technique
combines the advantages of little interference by statistical count
rate fluctuations and little influence by nonviable tumour zones
or partial volume effects. The other parameter we studied was
the volume of metabolically active tissue (MTV) disease. This was
selected by choosing a threshold SUV value, in which only voxels
with SUV values greater than or equal to the selected threshold
were included in the volume. All SUV measurements were
normalised for patient body weight (SUV). The relative changes
in tumour SUVs between baseline and follow-up were calculated
and correlated with subsequent histopathological tumour response
to therapy.
The percentage change (D) in each of the parameters (P)
between diagnosis (pre) and during treatment (intra) was
calculated using the following formula:
%DP¼f ½ Pintra Ppre =Ppreg 100
A negative value indicated a reduction in that parameter following
therapy and a positive value indicated an increase.
Histology
All the surgical specimens were classified by one experienced
pathologist (CM) who was unaware of the clinical and PET data
and who graded and staged the specimens in accordance with
the criteria of the International Union Against Cancer and the
American Joint Committee on Cancer Staging (Greene et al, 2002).
Tumour response to treatment was classified according to the
criteria described by Mandard et al (1994). Complete response
showed histologic fibrosis with or without inflammation extending
through the different layers of the oesophageal wall, but with no
viable residual tumour cells (TRG 1). Subtotal response (TRG 2)
was characterised by the presence of rare residual cancer cells
scattered through the fibrosis. An increase in the number of
residual cancer cells, but with fibrosis predominating, was termed
a partial response (TRG 3). Minimal response (TRG 4) showed
residual cancer outgrowing fibrosis. The absence of any regressive
changes (TRG 5) defined no change.
Statistical analysis
A statistical analysis was performed using commercial software
SPSS for Windows (version 12.0). Intraindividual comparisons
were performed using the Wilcoxon signed-rank test and
interindividual comparisons using Wilcoxon/Kruskal–Wallis.
The data were analysed in two ways: first designating a TRG of 1
and 2 as responders with the rest nonresponders and second
designating TRG of 1–3 as responders in keeping with the original
Mandard paper (Mandard et al, 1994).
RESULTS
The basic demographics are shown in Table 1. The median age was
59 years, there was a male preponderance, and a majority of
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spatients had adenocarcinoma. Most patients had clinical Stage 2
disease.
TRG 1 and 2 vs 3–5 (Table 2 and Figures 1 and 2)
Of the 32 patients, nine (28%) achieved a total or near total
response (TRG 1 or 2) and 23 (72%) had less or no response (TRG
3, 4 or 5). The 1-year survival in the TRG 1 and 2 group was 87%
compared with 67% in TRG 3–5 group (P¼0.091). There was no
significant correlation between either the initial SUV (P¼0.191) or
MTV (P¼0.472) scores and the final pathological response.
In the responder group 9 of 32, the mean (s.d.) SUV fell from 12.6
(6.3)gml
 1 pretreatment to 8.1 (2.9)gml
 1 following 1 week of
chemoradiation (P¼0.070), while in nonresponders (23 of 32), it
fell from 9.7 (5.4) to 7.1 (3.8)gml
 1, respectively (P¼0.003). The
MTV in good responders fell from 36.6 (22.7) to 22.3 (10.4)cm
3
during treatment (P¼0.180), while in nonresponders, this fell from
35.9 (36.7) to 31.9 (52.7)cm
3 (P¼0.405). There was a mean
reduction in SUV of 25.2 and 22.3% in responders and
nonresponders, respectively (P¼0.902). There was a mean reduc-
tion in MTV of 30.4 and 15.1% in responders and nonresponders,
respectively (P¼0.621). The change in SUV pretreatment and after
induction CRT was not significantly different between responders
and nonresponders (P¼0.645). Similarly, the change in MTV
pretreatment and after induction CRT was not significantly
different between responders and nonresponders (P¼0.305).
In an attempt to identify a threshold above or below which
response could be more accurately predicted, a reduction of more
than 20% in each of the parameters was used as a criterion. The
positive predictive values were 27 and 35% for changes in SUV and
Table 1 Patient characteristics
Male/female 34/7
Mean age (range) (years) 58 (37–74)
Pathology
Squamous cell 5
Adenocarcinoma 27
Grade
Well differentiated 1
Moderately differentiated 16
Poorly differentiated 13
Not evaluable 2
Primary site
Middle 4
Lower 16
O–G junction 12
Clinical stage
II 27
III 5
Radiotherapy dose
44Gy in 22 fractions 11
40.05Gy in 15 fractions 21
Fractions of RT completed before second PET
Mean 7
Range 5–10
CRT¼chemoradiation; Gy¼Gray; O–G¼oesophagogastric; PET¼positron emis-
sion tomography; RT¼radiotherapy.
Table 2 Evaluable patients – clinical stage, pathological response and FDG uptake
Patient
Pre-CRT
clinical stage TRG
Pathological
stage
SUV pre
(gml
 1)
SUV intra
(gml
 1)
Reduction
in SUV (%)
MTV pre
(gml
 1)
MTV intra
(gml
 1)
Reduction
in MTV (%)
1 T3N0M0 1 ypT0N0 6.3 5.9 6.4 24.6 19.2 21.9
2 T3N0M0 1 ypTxN0 6.1 3.5 42.6 13.4 3.7 72.1
3 T3N1M0 1 ypT0N0 12.8 11.5 10.4 35.6 34.5 3.2
4 T3N0M0 1 ypT0N0 12.8 12.8 0.0 35.3 22.4 36.5
5 T3N0M0 1 ypT0N0 9.8 9.5 3.0 19.6 20.6  5.0
6 T3N0M1a 2 ypT3N0 5.1 5.9  15.7 13.2 16.2  23.2
7 T3N0M0 2 ypT1N0 19.2 8.9 53.4 80.0 33.0 58.8
8 T3N0M0 2 ypT3N0 21.4 8.3 61.2 61.6 35.3 42.7
9 T3N0M0 2 ypT1N0 19.6 6.8 65.3 46.0 15.5 66.7
10 T3N0M0 3 ypT3N1 19.7 8.6 56.4 48.5 13.7 71.7
11 T3N1M0 3 ypT3N1 10.0 4.8 52.0 25.4 4.7 82.0
12 T3N0M0 3 ypT3N0 9.5 7.0 26.3 25.4 10.1 60.1
13 T3N0M0 3 ypT3N1 20.9 18.3 12.4 95.9 87.6 8.7
14 T3N1M0 3 ypT2N1 12.4 4.7 62.1 22.3 5.5 75.4
15 T3N1M0 3 ypT2N0 12.6 11.7 7.0 4.6 5.8  25.3
16 T3N0M0 3 ypT3N1 6.4 5.9 7.8 10.2 5.8 43.0
17 T3N0M0 3 ypT3N0 6.0 7.3  21.7 17.7 13.3 24.9
18 T3N0M0 3 ypT3N0 5.7 4.5 21.1 22.9 28.3  23.4
19 T2N1M0 3 ypT3N1 9.3 4.7 49.5 46.6 15.9 66.0
20 T3N0M0 3 ypT3N1 4.3 3.8 11.6 7.9 7.1 10.8
21 T3N0M0 3 ypT2N1 5.6 5.7  1.8 11.6 23.6  102.5
22 T3N0M0 3 ypT3N0 8.2 8.5  3.7 21.3 22.6  6.2
23 T3N0M0 3 ypT3N1 4.4 3.2 27.3 26.0 12.4 52.3
24 T3N0M0 3 ypT3N0 19.1 13.0 31.9 53.3 19.6 63.2
25 T3N0M0 3 ypT3N1 6.2 5.1 17.7 7.6 10.9  43.3
26 T3N0M0 3 ypT2N1 4.3 4.3 0.0 3.5 4.9  41.2
27 T3N0M0 3 ypT3N1 8.7 8.7 0.0 103.7 111.3  7.3
28 T3N0M0 4 ypT3N0 6.2 3.5 43.6 16.9 0.0 100.0
29 T3N0M0 4 ypT4N1 20.8 11.9 42.8 154.0 239.0  55.2
30 T3N0M0 4 ypT3N1 10.5 10.5 0.0 32.4 58.2  79.6
31 T3N1M0 4 ypT3N0 7.8 2.9 62.8 49.8 13.9 72.1
32 T3N0M0 4 ypT3N1 5.2 4.8 7.7 19.2 18.9 1.7
CRT¼chemoradiation; FDG¼fluorodeoxyglucose; intra¼during CRT; MTV¼metabolic tumour volume; pre¼before CRT; SUV¼mean maximum standardised uptake
value; TRG¼tumour regression grade.
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sMTV, respectively. The negative predictive values were 71 and
80%, respectively for the same parameters. No other cutoff value
was found to differentiate responding from nonresponding
tumours better.
TRG 1–3 vs TRG 4 and 5 (Table 2 and Figures 1 and 2)
In this analysis, there were 27 patients in the TRG 1–3 group
(responder) and five patients in the TRG 4 and 5 group
(nonresponder). There was no significant correlation between
either the initial SUV (P¼0.324) or MTV (P¼0.483) scores and
the final pathological response. In the responder group, the mean
(s.d.) maximum SUV fell from 10.6 (5.7)gml
 1 pretreatment to 7.5
(3.5)gml
 1 following 1 week (P¼0.002). In nonresponders, the
results were 10.1 (6.3) and 6.7 (4.2)gml
 1, respectively (P¼0.125).
The MTV in responders fell from 32.7 (26.8) to 22.3 (24.3)cm
3
during treatment (P¼0.124), while in nonresponders, this rose
from 54.5(57.2) to 66.0 (99.1)cm
3 (P¼0.893). The change in SUV
pretreatment and after induction CRT was not significantly
different between responders and nonresponders (P¼0.640).
Similarly, the change in MTV pretreatment and after induction
CRT was not significantly different between responders and
nonresponders (P¼0.517). There was a mean reduction in SUV
of 21.6 and of 31.4% in responders and nonresponders,
respectively (P¼0.479). There was a mean reduction in MTV of
21.6 and 7.8% in responders and nonresponders, respectively
(P¼0.841). Using a greater than 20% threshold, the positive
predictive values were 80 and 88% for changes in mean maximum
SUV and MTV, respectively.
DISCUSSION
In contrast to endoscopic ultrasound and CT imaging, which
cannot differentiate fibrous tissue from viable tumour tissue in
patients undergoing neoadjuvant treatment regimens, FDG-PET
scanning holds greater promise. It monitors glucose turnover in
glucose-avid tumour cells, and, intuitively, diminished metabolism
should be anticipated to correlate with a tumour response.
Moreover, the metabolic changes may precede structural changes,
and this has been confirmed for certain solid tumours (Smith,
1998). The advent of PET/CT has enhanced the anatomic
localisation of lung tumours (Lardinois et al, 2003). To our
knowledge, there have not been equivalent studies in oesophageal
cancer. However, the recording of SUV or MTV would not have
been altered by the addition or absence of the CT component.
In studies in oesophageal cancer, the FDG-PET scan has
predominantly been performed following completion of the
neoadjuvant protocol, as distinct from early in the treatment
(Bru ¨cher et al, 2001; Arslan et al, 2002; Flamen et al, 2002; Kato
et al, 2002; Downey et al, 2003; Brink et al, 2004; Wieder et al,
2004). The evidence from these studies suggests that FDG-PET
scans following treatment significantly correlates with pathologic
response and survival. Bru ¨cher et al (2001) prospectively evaluated
37 patients following chemoradiation for T2–4 squamous cell
tumours, of whom 24 proceeded to surgery. [
18F]-fluorodeoxy-
glucose-PET was performed at the completion of chemoradiation,
and responders were defined as less than 10% viable tumour cells,
correlating closely with TRG 1 and 2 in this study, FDG uptake
decreased by 72711%, while in nonresponders, the decrease was
significantly (P¼0.002) less at 42722%, and this was associated
with worse overall survival. Brink et al (2004) prospectively
studied 20 consecutive patients who underwent surgery following
chemoradiation. Although the SUV decreased (Po0.01) in all
patients following the neoadjuvant component, the percentage
change did not differ significantly between responders and
nonresponders.
An early marker of response offers the greatest potential clinical
advantage, particularly if those not benefiting from treatment
could be identified and offered alternative approaches, and this
was the hypothesis evaluated in this study. In a similar study, but
using chemotherapy alone, Weber et al (2001) performed the
second PET scan in 40 consecutive patients just before the second
of two cycles of chemotherapy. A significant difference in tumour
FDG uptake between responders and nonresponders was observed
and, applying a cutoff value of 35% reduction of initial FDG uptake
as a criterion for metabolic response, they were able to predict
clinical response with 93% sensitivity and 95% specificity. Where
early sequential chemoradiation was employed, the most compar-
able study is from Wieder et al (2004), who performed the second
PET scan following 2 weeks of neoadjuvant chemoradiation in
27 patients with oesophageal squamous cell cancer. Mean tumour
SUV in the group was 9.372.8gml
 1 before therapy and
decreased to 5.771.9gml
 1 ( 38718%; Po0.001) after 2 weeks.
In histopathologic responders, equivalent to TRG 1 and TRG 2, the
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sdecrease in SUV from baseline to day 14 was 44715%, whereas it
was only 21714% in nonresponders (P¼0.005). Although in the
present series both the maximum SUV and MTV decreased more
in responders compared with nonresponders, this does not
approach significance. There are some differences in this study
and that of the Munich group (Wieder et al, 2004): the report by
the Munich group was in squamous cell cancer, whereas this study
was predominantly in patients with adenocarcinoma; the second
week of induction CRT was completed in the Munich study before
the second FDG-PET scan was performed, in contrast to this study
where the second scan was performed after 1 week of induction
therapy.
It is likely that the inflammatory response to radiation obscures
changes in tumour glucose metabolism associated with treatment
effect (Hautzel and Muller-Gartner, 1997). This effect would be
expected in both responders and nonresponders and might mask a
reduction in SUV. It is difficult to suggest that this would be any
different at 2 weeks. Although it is possible that larger sample sizes
may help discriminate responders and nonresponder, the observa-
tion that a decrease in SUV and MTV is frequently observed in
patients who do not achieve a major histomorphologic response
at least suggests that early sequential scans in patients receiving
radiation as part of their induction regimen is unlikely to be a
good discriminant of response or resistance.
In conclusion, the hypothesis that histological tumour res-
ponses at surgery after induction CRT may be identified by
early FDG-PET scans has not been proven. These results appear
to contradict previously reported findings (Weber et al, 2001,
2004), but an early inflammatory response to radiation even
at 7 days may be the confounding variable. Larger studies are
required, but response evaluation using metabolic imaging
might be easier to evaluate in trials of induction chemotherapy
alone or new biological agents, before the administration of
radiation therapy.
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